Straits Times Index
3,345.33 +8.74 (+0.26%) Nikkei
38,923.03 +435.13 (+1.13%) Hang Seng
18,403.04 +323.43 (+1.79%) FTSE 100
8,291.40 +16.02 (+0.19%) Bitcoin USD
69,272.59 +1,550.46 (+2.29%) CMC Crypto 200
1,489.70 +21.76 (+1.48%)
Dynavax Technologies Corporation (0IDA.L)
| Previous close | 11.77 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,118 |
| Market cap | 250.573M |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
Dynavax Technologies said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve the expanded use of its hepatitis B vaccine in patients undergoing hemodialysis, citing insufficient safety and effectiveness data. The FDA, in its so-called "complete response letter", stated that the data was insufficient as a third-party clinical trial site operator had destroyed data source documents for about half of the subjects enrolled in the vaccine's trial, according to the company. Dynavax's vaccine, Heplisav-B, was first approved by the FDA in 2017, having been rejected twice before in 2013 and 2016 over unresolved safety concerns.
- Simply Wall St.
Analysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter Results
Dynavax Technologies Corporation ( NASDAQ:DVAX ) just released its latest first-quarter report and things are not...
- GuruFocus.com
Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...
Comprehensive Analysis of Dynavax's Financial Performance and Strategic Initiatives
